Summary: Traditional endpoints such as progression-free survival and overall survival do not fully capture the pharmacologic and pharmacodynamic effects of a therapeutic intervention. Incorporating mechanism-driven biomarkers and validated surrogate proximal endpoints can provide orthogonal readouts of anti-tumor activity and delineate the relative contribution of treatment components on an individual level, highlighting the limitation of solely relying on aggregated readouts from clinical trials to facilitate go/no-go decisions for precision therapies.

中文翻译：

---

当代精准肿瘤学试验的精准终点

摘要：无进展生存期和总生存期等传统终点并不能完全反映治疗干预的药理学和药效学效果。结合机制驱动的生物标志物和经过验证的替代近端终点可以提供抗肿瘤活性的正交读数，并描述治疗成分在个体水平上的相对贡献，突显了仅依靠临床试验的汇总读数来促进通过/不通过的局限性。做出精准治疗的决定。